Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Operating Income (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Operating Income for 8 consecutive years, with -$84.2 million as the latest value for Q1 2026.

  • For Q1 2026, Operating Income fell 13.07% year-over-year to -$84.2 million; the TTM value through Mar 2026 reached -$359.1 million, down 29.08%, while the annual FY2025 figure was -$349.4 million, 33.54% down from the prior year.
  • Operating Income hit -$84.2 million in Q1 2026 for Kymera Therapeutics, up from -$97.9 million in the prior quarter.
  • Across five years, Operating Income topped out at -$19.3 million in Q4 2023 and bottomed at -$97.9 million in Q4 2025.
  • Average Operating Income over 5 years is -$60.1 million, with a median of -$57.5 million recorded in 2023.
  • Year-over-year, Operating Income skyrocketed 50.01% in 2023 and then plummeted 318.16% in 2024.
  • Kymera Therapeutics' Operating Income stood at -$38.6 million in 2022, then surged by 50.01% to -$19.3 million in 2023, then tumbled by 318.16% to -$80.8 million in 2024, then fell by 21.23% to -$97.9 million in 2025, then increased by 14.04% to -$84.2 million in 2026.
  • According to Business Quant data, Operating Income over the past three periods came in at -$84.2 million, -$97.9 million, and -$92.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.